German is available via eTranslation, the European Commission's machine translation service.
Translate to German | Important information about machine translation
For more information about COVID-19, see:
The table below lists the COVID-19 vaccines that are authorised for use in the EU, including originally authorised and adapted vaccines.
Adapted vaccines are intended to provide broader protection against different virus variants following initial vaccination.
Companies marketing originally authorised vaccines can apply to change the marketing authorisation to include an adapted version, which is shown in italics in the table below.
| Vaccine | Marketing authorisation holder | Key milestones | More information |
|---|---|---|---|
| Kostaive | Seqirus Netherlands B.V. | Marketing authorisation issued: 12/02/2025 | |
| Nuvaxovid | Novavax CZ, a.s. |
Nuvaxovid XFG (adapted) authorised: 28/07/2026 Nuvaxovid JN.1 (adapted) authorised: 08/10/2024 Nuvaxovid XBB.1.5 (adapted) authorised: 31/10/2023 Standard marketing authorisation issued: 04/07/2023 Annual renewal issued: 03/10/2022 Conditional marketing authorisation issued: 20/12/2021 |
Nuvaxovid: product information Clinical data (login required) |
| Spikevax (previously COVID-19 Vaccine Moderna) | Moderna Biotech Spain S.L. |
Spikevax XFG (adapted) authorised: 28/07/2026 Spikevax LP.8.1 (adapted) authorised: 25/07/2025 Spikevax JN.1 (adapted) authorised: 10/09/2024 Spikevax XBB.1.5 (adapted) authorised: 15/09/2023 Spikevax bivalent Original/Omicron BA.4-5 (adapted) authorised: 20/10/2022 Standard marketing authorisation issued: 03/10/2022 Spikevax bivalent Original/Omicron BA.1 (adapted) authorised: 01/09/2022 Annual renewal issued: 04/10/2021 Conditional marketing authorisation issued: 06/01/2021 |
Clinical data (login required)
|
| Comirnaty | BioNTech Manufacturing GmbH |
Comirnaty XFG (adapted) authorised: 28/07/2026 Comirnaty LP.8.1 (adapted) authorised: 25/07/2025 Comirnaty KP.2 (adapted) authorised: 26/09/2024 Comirnaty JN.1 (adapted) authorised: 03/07/2024 Comirnaty Omicron XBB.1.5 (adapted) authorised: 31/08/2023 Standard marketing authorisation issued: 10/10/2022 Comirnaty Original/Omicron BA.4-5 (adapted) authorised: 12/09/2022 Comirnaty Original/Omicron BA.1 (adapted) authorised: 01/09/2022 Annual renewal issued: 03/11/2021 Conditional marketing authorisation issued: 21/12/2020 |
Clinical data (login required)
|
| Bimervax (previously COVID-19 Vaccine HIPRA) | HIPRA Human Health S.L.U. |
Bimervax XFG (adapted) authorised: 28/07/2026 Bimervax LP.8.1 (adapted) authorised: 19/9/2025 Bimervax XBB.1.16 (adapted) authorised: 17/10/2024 Marketing authorisation issued: 30/03/2023 |
Clinical data (login required) |
| mCombriax | Moderna Biotech Spain S.L | Marketing authorisation issued on 20/04/2026 | |
| mNexspike | Moderna Biotech Spain S.L | Marketing authorisation issued on 12/02/2026 |
For more information on how EMA evaluated these vaccines, see:
The following treatments can be used in the EU to treat COVID-19:
| Treatment | Status | More information |
|---|---|---|
| Kavigale (sipavibart) | Marketing authorisation issued: 20/01/2025 | |
| Gohibic (vilobelimab) | Marketing authorisation issued: 13/01/2025 | |
| Paxlovid (nirmatrelvir / ritonavir) |
Marketing authorisation granted: 24/02/2023 Conditional marketing authorisation granted: 28/01/2022 |
|
| RoActemra (tocilizumab) | Marketing authorisation for COVID-19 indication granted: 06/12/2021 | Latest news |
| Veklury (remdesivir) |
Marketing authorisation granted: 08/08/2022 Conditional marketing authorisation granted: 03/07/2020 |
Clinical data (login required) |
| Avtozma (tocilizumab) | Marketing authorisation issued on 14/02/2025 | |
| Tocilizumab STADA (previously Tofidence) | Marketing authorisation issued on 20/06/2024 | |
| Tuyory (tocilizumab) | Marketing authorisation issued on 27/04/2026 | |
| Tyenne (tocilizumab) | Marketing authorisation issued on 15/09/2023 | |
| Kineret (anakinra) | Marketing authorisation issued on 08/03/2022 |
For more information on how EMA fast-tracks its evaluation of promising potential COVID-19 medicines, see:
EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any rare side effects that may emerge once many millions of people are vaccinated.
Safety information on each COVID-19 vaccine is available:
Information on ongoing clinical trials for COVID-19 treatments in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):
Users can find information on:
Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.
For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see:
An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.
The tracking of updates begins in September 2026.
4 September 2026
1 September 2026